SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 425 - Prospectuses and communications, business combinations:
SEC Accession No. 0001193125-21-230209
Filing Date
2021-07-30
Accepted
2021-07-30 07:58:00
Documents
2

Document Format Files

Seq Description Document Type Size
1 425 d154077d425.htm 425 42442
2 GRAPHIC g154077g0729125403779.jpg GRAPHIC 3961
  Complete submission text file 0001193125-21-230209.txt   49641
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filed by) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 425
SIC: 2834 Pharmaceutical Preparations

Mailing Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 844-445-5704
Xeris Biopharma Holdings, Inc. (Subject) CIK: 0001867096 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 425 | Act: 34 | File No.: 333-257642 | Film No.: 211130140
SIC: 2834 Pharmaceutical Preparations